Drug
ES014
ES014 is a pharmaceutical drug with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_1
2
50%
Ph phase_2
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Terminated(1)
Detailed Status
Recruiting2
Active, not recruiting1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
recruiting250%
active_not_recruiting125%
withdrawn125%
Recent Activity
3 active trials
Showing 4 of 4
recruitingphase_2
A Study in Adults With Desmoid Tumors
NCT07541430
active_not_recruitingphase_1
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours
NCT05717348
recruitingphase_2
A Study of ES014 in Subjects With Advanced Solid Tumors
NCT06543056
withdrawnphase_1
A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
NCT05381935
Clinical Trials (4)
Showing 4 of 4 trials
NCT07541430Phase 2
A Study in Adults With Desmoid Tumors
NCT05717348Phase 1
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours
NCT06543056Phase 2
A Study of ES014 in Subjects With Advanced Solid Tumors
NCT05381935Phase 1
A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4